Insider Selling: Evolus (NASDAQ:EOLS) Insider Sells 13,669 Shares of Stock

Evolus, Inc. (NASDAQ:EOLS) insider David Moatazedi sold 13,669 shares of the stock in a transaction that occurred on Friday, March 20th. The stock was sold at an average price of $4.75, for a total transaction of $64,927.75. Following the completion of the sale, the insider owned 604,700 shares of the company’s stock, valued at approximately $2,872,325. The trade was a 2.21% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

David Moatazedi also recently made the following trade(s):

• On Tuesday, March 17th, David Moatazedi sold 116,720 shares of Evolus stock. The shares were sold at an average price of $4.89, for a total transaction of $570,760.80.
• On Monday, December 22nd, David Moatazedi sold 10,539 shares of Evolus stock. The stock was sold at an average price of $7.15, for a total transaction of $75,353.85.

Evolus Price Performance

Shares of NASDAQ:EOLS traded down $0.22 during midday trading on Friday, hitting $4.64. 1,596,877 shares of the stock were exchanged, compared to its average volume of 1,553,567. Evolus, Inc. has a 52-week low of $4.09 and a 52-week high of $13.30. The business’s fifty day simple moving average is $4.79 and its two-hundred day simple moving average is $6.05.

Evolus (NASDAQ:EOLS) last issued its earnings results on Tuesday, March 3rd. The company reported $0.00 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.09). The business had revenue of $90.30 million during the quarter, compared to analysts’ expectations of $89.58 million. As a group, sell-side analysts predict that Evolus, Inc. will post -0.61 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on EOLS shares. HC Wainwright dropped their price objective on Evolus from $20.00 to $13.00 and set a “buy” rating on the stock in a report on Tuesday, February 3rd. Wall Street Zen downgraded shares of Evolus from a “buy” rating to a “hold” rating in a research report on Sunday, March 15th. Stifel Nicolaus dropped their price target on shares of Evolus from $20.00 to $17.00 and set a “buy” rating on the stock in a research note on Tuesday, January 13th. Weiss Ratings restated a “sell (e+)” rating on shares of Evolus in a report on Monday, December 22nd. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Evolus in a research note on Wednesday, December 24th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.00.

Institutional Investors Weigh In On Evolus

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Nantahala Capital Management LLC grew its holdings in Evolus by 1.6% during the fourth quarter. Nantahala Capital Management LLC now owns 5,820,649 shares of the company’s stock valued at $38,707,000 after purchasing an additional 93,792 shares during the last quarter. Caligan Partners LP lifted its stake in shares of Evolus by 23.8% in the third quarter. Caligan Partners LP now owns 4,138,943 shares of the company’s stock worth $25,413,000 after buying an additional 796,973 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Evolus by 3.3% during the 3rd quarter. Vanguard Group Inc. now owns 3,428,943 shares of the company’s stock worth $21,054,000 after buying an additional 110,693 shares during the period. Braidwell LP bought a new stake in shares of Evolus during the 4th quarter worth $20,650,000. Finally, Frazier Life Sciences Management L.P. bought a new stake in shares of Evolus during the 2nd quarter worth $22,431,000. 90.69% of the stock is currently owned by institutional investors and hedge funds.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.